Pfizer profit beats estimates on higher demand for COVID products

Revenue from the antiviral pill, Paxlovid, exceeded market estimates by more than $1b, while vaccine sales surged 20%, helping the drugmaker reaffirm the combined 2022 revenue forecast of $54b.